Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: Data from the autoimmunity and rituximab registry

Arthritis Care and Research

Volumn 65, Issue 11, 2013, Pages 1874-1879

  Godot, S ^a   Gottenberg, J E ^b   Paternotte, S ^c   Pane, I ^d   Combe, B ^a,e   Sibilia, J ^b   Flipo, R M ^f   Schaeverbeke, T ^g   Ravaud, P ^d   Toussirot, E ^a,h   Berenbaum, F ^a   Mariette, X ^a   Wendling, D ⁱ   Sellam, J ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Paris v University ^*  (France)

^d HÔTEL DIEU   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f UNIV LILLE   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CORTICOSTEROID; METHYLPREDNISOLONE; RITUXIMAB;

ABDOMINAL SURGERY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; DEEP VEIN THROMBOSIS; ENTEROCUTANEOUS FISTULA; FEMALE; FOLLOW UP; HIP ARTHROPLASTY; HUMAN; INTERVERTEBRAL DISK DEGENERATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; ORTHOPEDIC SURGERY; PNEUMONIA; PROSTHESIS INFECTION; RHEUMATOID ARTHRITIS; SAFETY; SEPTIC SHOCK; SIGMOIDECTOMY; SURGICAL INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 84887046316     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22056     Document Type: Article

References (15)

1. Luessenhop CP, Higgins LD, Brause BD, Ranawat CS,. Multiple prosthetic infections after total joint arthroplasty: risk factor analysis. J Arthroplasty 1996; 11: 862-8.
2. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1713-20.
3. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55: 333-7.
4. Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 689-95.
5. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-α blockers decreases complications? Rheumatology (Oxford) 2010; 49: 341-7.
6. Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 2013; 23: 440-9.
7. Mariette X, Gottenberg JE, Ravaud P, Combe B,. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
8. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al, on behalf of the Investigators of the AutoImmunity and Rituximab Registry and the French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2625-32.
9. Saech J, Maizus K, Owczarczyk K, Roehrs T, Benenson E, Rubbert A,. Rituximab in patients with rheumatoid arthritis and surgical intervention [abstract]. Ann Rheum Dis 2009; 68 Suppl: 443.
10. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM,. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 9203-8.
11. Sibilia J, Gottenberg JE, Mariette X,. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008; 75: 526-32.
12. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011; 10: 624-30.
13. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K,. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis 2011; 14: 31-6.
14. Wendling D, Balblanc JC, Brousse A, Wendling D, Balblanc JC, Brousse A, et al. Surgery in patients receiving anti-tumour necrosis factor α treatment in rheumatoid arthritis: an observational study on 50 surgical procedures [letter]. Ann Rheum Dis 2005; 64: 1378-9.
15. Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al. Rituximab (MabThera) therapy and safety management: clinical tool guide. Joint Bone Spine 2008; 75 Suppl: S1-99.